Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Monte Rosa Therapeutics (GLUE) EPS (Basic) (2023 - 2025)

Monte Rosa Therapeutics' EPS (Basic) history spans 3 years, with the latest figure at -$0.55 for Q4 2025.

  • For Q4 2025, EPS (Basic) fell 339.13% year-over-year to -$0.55; the TTM value through Dec 2025 reached -$0.46, up 54.9%, while the annual FY2025 figure was -$0.46, 53.06% up from the prior year.
  • EPS (Basic) reached -$0.55 in Q4 2025 per GLUE's latest filing, down from -$0.33 in the prior quarter.
  • In the past five years, EPS (Basic) ranged from a high of $0.57 in Q1 2025 to a low of -$0.71 in Q2 2023.
  • Average EPS (Basic) over 3 years is -$0.34, with a median of -$0.48 recorded in 2024.
  • The largest YoY upside for EPS (Basic) was 207.55% in 2025 against a maximum downside of 339.13% in 2025.
  • A 3-year view of EPS (Basic) shows it stood at -$0.57 in 2023, then skyrocketed by 140.35% to $0.23 in 2024, then plummeted by 339.13% to -$0.55 in 2025.
  • Per Business Quant, the three most recent readings for GLUE's EPS (Basic) are -$0.55 (Q4 2025), -$0.33 (Q3 2025), and -$0.15 (Q2 2025).